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Tuberculosis (TB) is the most common cause of asymptomatic 
cervical lymphadenopathy in South Africa (SA). It is also a ‘great 
masquerader’, as it features nonspecific symptoms that can be 
confused with a number of other diseases. In a TB-endemic area, 
where the disease is front-of-mind for clinicians, lymphadenopathy 
may be misattributed to TB and obscure a cancer diagnosis or 
other cause. In particular, the misdiagnosis of lymphoma as TB 
has been highlighted in a number of African studies, which show 
that 25 - 85% of lymphoma patients are on TB therapy at the 
time of lymphoma diagnosis, the majority of whom did not have 
proven TB.[1-4] Further complicating diagnosis, people living with 
HIV (PLHIV) are at an increased risk of both TB and lymphoma 
(as well as other malignancies such as Kaposi sarcoma, which 
may involve the lymph nodes). The increased risk of lymphoma 
persists despite antiretroviral treatment (ART),[5] and in highly 
developed countries, lymphoma is the leading cause of HIV 
mortality.[6,7] 
Challenges in the diagnosis of lymphoma have been highlighted 
and lymphoma has been identified as having the second longest time 
from symptom onset to diagnosis of any malignancy.[8] Numerous 
barriers to the diagnosis of lymphoma are described, such as the 
insidious onset of symptoms and lack of specificity for diagnosis; 
lack of a distinct referral pathway; low sensitivity of the fine-needle 
aspiration (FNA) for lymphoma; and barriers in obtaining a lymph 
node biopsy.[9,10] In TB-endemic areas, there are further barriers 
to TB misdiagnosis, which occur owing to overlapping symptoms 
(cough, loss of weight and night sweats); investigation findings 
(cytopenias, pleural effusions and hypodense lesions in the spleen); 
and nonspecific cytological findings (poorly formed granulomas that 
can be seen in both diseases). Furthermore, both TB and lymphoma 
have been described as having an onset diagnosed after immune 
reconstitution (TB/lymphoma immune reconstitution inflammatory 
syndrome (IRIS)), which may overlap in clinical presentation. 
Lastly, an important relationship between these diseases is that 
lymphoma is associated with a high risk of TB, possibly due to 
immune suppression, with a hazard ratio of 2.7 (p<0.01) for developing 
TB compared with population controls.[11] The relationship between 
HIV, TB and lymphoma places PLHIV in a TB-endemic area at an 
especially vulnerable risk of misdiagnosis of lymphoma (or other 
malignancy) as TB.
The misdiagnosis of lymphoma or any other malignancy as TB 
adenitis results in delayed diagnosis and poorer outcome in 
lymphoma patients with more advanced disease at presentation.[12] 
Making a timely and accurate diagnosis of the underlying cause 
for adenopathy is therefore critical, especially considering that 
lymphoma typically involves younger patients and is highly curable 
in the early stages. 
Commonly performed tests on 
lymph node tissue, applications and 
limitations
Smear for acid-fast bacilli in tuberculosis
An air-dried smear for acid-fast bacilli (AFB) is a commonly 
performed investigation for the diagnosis of TB adenitis, as it is 
easy to perform from an FNA and has a quick turn-around-time 
(TAT). However, the test is limited by a poor sensitivity of 8 - 35%.[13-16] 
When positive, the test is useful, as it is highly specific, with the AFB 
identified signifying Mycobacterium tuberculosis (adenitis due to 
other types of AFB are very uncommon and typically only seen in 
non-bacille Calmette-Guérin (BCG)-immunised children).[17] Similar 
to sputum, AFBs on lymph node aspirate have been out-performed 
by the newer nucleic acid amplification tests for TB, such as the 
GeneXpert MTB/RIF (Cepheid, USA) (discussed below) and should 
be superseded by these testing methods. 
Fine-needle aspiration for cytology 
Fine-needle aspiration for cytology (FNAC) is a poor test for the 
diagnosis of lymphoma, especially in the absence of flow cytometry 
and immunohistochemistry. At our institution, we have shown that 
cytological findings are ‘suggestive of lymphoma’ in only 11% of 
lymphoma cases.[12] Cytology also has a long TAT, is labour intensive 
and is expensive. Despite these limitations, misconceptions around 
its use abound, as demonstrated by a cohort from our institution 
showing that an FNAC is often repeated when the clinician suspects 
lymphoma and the first test was negative.[12] There are numerous 
articles on the use of FNAC in the diagnosis of lymphoma, and wide 
variations in reported accuracy. A recent meta-analysis reported a 
‘median actionable diagnosis’ of 74% for FNAC,[18] but it is important 
to note that the meta-analysis did not attempt to address diagnostic 
accuracy. The single article in this meta-analysis that discussed 
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diagnostic accuracy by centralised review of specimens submitted for 
a clinical trial (i.e. FNAC and excisional biopsy results independently 
correlated) and that reflected community practice (i.e. FNACs 
performed by different pathologists at different centres), reported 
only 12% diagnostic accuracy of FNAC for lymphoma, and 29% when 
immunophenotyping was included.[19] 
Cytology has a higher sensitivity for metastatic malignancy 
involving a lymph node, but there are also highly variable sensitivity 
rates reported in the literature. Even in a perioperative setting of 
patients undergoing surgery for breast cancer, the false-negative rate 
of FNA of axillary lymph nodes (under ultrasound guidance) has 
been shown to be too high (30%) to replace excision biopsy.[20] Due 
to the low negative predictive value of the FNAC from a lymph node, 
especially in lymphoma, the test may be useful where disseminated 
malignancy is highly suspected, but it should not be employed as a 
‘rule-out’ test for either lymphoma or malignancy. 
GeneXpert MTB/RIF for tuberculosis on a lymph node 
A GeneXpert MTB/RIF assay on lymph node tissue was recently 
recommended by the World Health Organization (WHO) as the 
first-line investigation in suspected TB lymphadenitis. This follows 
a Cochrane review showing a pooled sensitivity and specificity 
against culture of 87% (range 36 - 100%) and 86% (range 39 - 100%), 
respectively.[21] GeneXpert MTB/RIF has recently been superseded 
by the GeneXpert MTB/RIF Ultra assay (Ultra), which has greater 
sensitivity for the detection of M. tuberculosis complex owing to a 
lower limit of detection (Ultra 15.6 CFU/mL v. Xpert 114 CFU/mL). 
The greatest use of the Ultra is in paucibacillary samples, such as 
those from lymph node tissue. These tests are cartridge based and 
have a fast TAT of 24 h. These can be performed from an FNA by 
flushing the needle and syringe with 1 - 2 mL normal saline (even 
when the syringe and needle appear empty macroscopically) and 
by sending it in a clean specimen container, or by sending a small 
amount of tissue obtained by biopsy. 
Culture of material obtained by fine-needle aspiration 
or biopsy for tuberculosis
Culture for M. tuberculosis from lymph node tissue and FNA 
performs poorly owing to a paucibacillary environment, harsh 
decontamination procedures and potential sampling error.[17,22] The 
sensitivity of mycobacterial culture from FNA may vary depending 
on whether the node is caseous. It has been variably reported, but 
is ~17% with culture of an FNA, following excisional biopsy at 40 - 
60%.[17] Other limitations of culture in practice are a very long TAT 
of up to 6 weeks, making the test impractical as an initial diagnostic 
procedure. The usefulness of culture on lymph node is therefore on 
tissue (rather than FNA). 
Core biopsy for diagnosis of lymphoma
We refer to core biopsy with a wide needle, i.e 14G or 16G, 
which is different from the fine-needle aspiration biopsy (FNAB) 
commonly referred to in clinical practice. Core biopsy of lymph 
nodes is a minimally invasive technique that can obviate the need for 
excision biopsy. Core biopsy is useful for diagnosing the aetiology of 
lymphadenopathy in HIV-infected patients.[23] It is more frequently 
employed as the first step in tissue sampling in patients with 
suspected lymphoma, as it is safe and has up to an 89% diagnostic 
yield with a 14G or 16G needle. An automated device (‘gun biopsy’) 
has been safely and successfully used as a method of performing a 
core biopsy in patients with lymphoma,[24] as well as in HIV and TB 
lymphadenitis patients.[23] The automated device is preferred because 
the tissue cylinder of the biopsy retains the architecture of the tissue, 
and the speed of the cutting mechanism provides a clean edge with 
less shearing artefact.[24] The procedure can be performed in the 
consulting room and has a low risk of complications. In our practice, 
we have found it difficult to perform in cases where a lymph node is 
<15 mm; an excision biopsy is then preferable. Where possible, a core 
biopsy should be performed under ultrasound guidance. 
Excision biopsy
An excision biopsy remains the optimal choice for histological 
evaluation, but has significant cost (surgical time and expertise) 
and anaesthetic and surgical risks, even though the risks are 
low. An excision biopsy allows for the entire nodal architecture 
to be evaluated, as well as providing ample tissue for immuno -
histochemical staining, which might influence the ability to subtype 
the lymphoma. 
Conclusions and suggested diagnostic 
approach
Patients with lymphadenopathy are at high risk of delayed diagnosis 
or misdiagnosis of the underlying disease, despite improvement 
in diagnostic tests. Currently, new-generation TB tests have not 
been incorporated into widely practised diagnostic algorithms and 
there is a need to educate clinicians and students about these tests 
and techniques. Where a lymph node is amenable to biopsy, a 
presumptive course of TB therapy in the era of new TB diagnostic 
tests is an unnecessarily hazardous practice. The risks of presumptive 
TB therapy include not only delaying making the correct diagnosis 
with the resultant morbidity, but also the potential for harmful side-
effects from TB drugs and failure to diagnose drug-resistant TB. 
A more challenging situation is where lymphadenopathy is in 
an anatomical area where it is difficult to perform a biopsy. In 
these instances, a bronchoscopy/mediastinoscopy or laparoscopic 
biopsy should be performed, if possible, and there should be 
early involvement of the haematologist for diagnostic assistance, as 
ancillary tests such as flow cytometry or bone marrow biopsy may 
be useful in selected cases. In the few cases where tissue cannot 
be obtained due to site or technical difficulties, and patients with 
adenopathy are administered empirical TB therapy, they require 
close review to ascertain unequivocal response within 2 weeks, 
preferably by the clinician who initiated TB treatment. 
We suggest a very simple approach to peripheral lymphadenopathy 
that can be followed in most adults presenting with an enlarged 
peripheral lymph node. In most patients, start with a GeneXpert 
(or Ultra) with FNA and check the results in 2 days. If the FNA 
GeneXpert is negative, proceed to a core biopsy with a 14G needle 
for histological evaluation (preferably providing 2 - 4 core biopsy 
specimens), repeat the GeneXpert and request TB culture on the 
tissue obtained. If the core biopsy is non-diagnostic, refer the patient 
for a surgical excision biopsy. FNAC may be reserved for patients 
strongly suspected of having head and neck cancer or disseminated 
malignancy. In patients in whom TB is an unlikely diagnosis, an FNA 
need not be carried out and a core biopsy with both GeneXpert and 
histological evaluation is a reasonable first investigation. 
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